Target Gene/Pathway Pathway / Gene
Search results
Showing 1 to 10 of 140 entries
| No. | KEGG GENES | KEGG PATHWAY | KEGG DRUG | DrugBank | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
ABL1
💬1. ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signalin ... | Nilotinib
Nilotinib
💬1. ABL1
| Nilotinib | 5件: 6 6, 8, 34, 51, 86 💬
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 |
ABL1
💬2. ABL1
| 11件: ErbB signaling pathway ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signalin ... | Imatinib
Imatinib
💬2. ABL1
| Imatinib | 12件: 13 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬2. ABL1
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3 |
ADRA2A
💬3. ADRA2A
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Dexmedetomidine
Dexmedetomidine
💬3. ADRA2A
| Dexmedetomidine | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬3. ADRA2A
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 4 |
ADRA2B
💬4. ADRA2B
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Dexmedetomidine
Dexmedetomidine
💬4. ADRA2B
| Dexmedetomidine | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬4. ADRA2B
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 |
ADRA2C
💬5. ADRA2C
| 2件: cGMP-PKG signaling pathway cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction | Dexmedetomidine
Dexmedetomidine
💬5. ADRA2C
| Dexmedetomidine | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬5. ADRA2C
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 6 |
ALK
💬6. ALK
| 3件: Pathways in cancer Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer 3件: Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in ... | Crizotinib
Crizotinib
💬6. ALK
| Crizotinib | 1件: 34 34 💬6. ALK
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 7 |
ALK
💬7. ALK
| 3件: Pathways in cancer Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer 3件: Pathways in cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in ... | Brigatinib
Brigatinib
💬7. ALK
| Brigatinib | 1件: 34 34 💬7. ALK
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 8 |
AXL
💬8. AXL
| 1件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance | Cabozantinib
Cabozantinib
💬8. AXL
| Cabozantinib | 1件: 34 34 💬8. AXL
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 9 |
BRAF
💬9. BRAF
| 44件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer 44件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB s ... | Dabrafenib
Dabrafenib
💬9. BRAF
| Dabrafenib | 1件: 34 34 💬9. BRAF
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10 |
BRAF
💬10. BRAF
| 44件: EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, FoxO signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Focal adhesion, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Long-term depression, Regulation of actin cytoskeleton, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Alcoholism, Hepatitis C, Hepatitis B, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Thyroid cancer, Melanoma, Bladder cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer 44件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB s ... | Sorafenib
Sorafenib
💬10. BRAF
| Sorafenib | 2件: 34 34, 86 💬
|